Trial Profile
A Phase 1a/1b Dose Escalation and Expansion Study of SC-003 as a Single-Agent and in Combination With ABBV-181 in Subjects With Platinum-Resistant/ Refractory Ovarian Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2020
Price :
$35
*
At a glance
- Drugs Budigalimab (Primary) ; SC 003 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; First in man
- Sponsors Stem CentRx
- 05 Jun 2020 Results assessing safety/tolerability, pharmacokinetics, and preliminary antitumor activity of SC-003 alone or in combination with budigalimab in patients with ovarian cancer, published in the Gynecologic Oncology.
- 02 Jan 2019 Status changed from active, no longer recruiting to discontinued.
- 30 Nov 2018 Status changed from recruiting to active, no longer recruiting.